BACKGROUND: Chronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by tissue eosinophilia that is associated with poor prognosis. Recent findings that proton pump inhibitors (PPIs) directly modulate the expression of eotaxin-3, an eosinophil chemoattractant, in patients with eosinophilic diseases suggest therapeutic potential for PPIs in those with CRSwNP. OBJECTIVE: We assessed the effect of type 2 mediators, particularly IL-13 and eotaxin-3, on tissue eosinophilia and disease severity in patients with chronic rhinosinusitis (CRS). Further investigation focused on PPI suppression of eotaxin-3 expression in vivo and in vitro, with exploration of underlying mechanisms. METHODS: Type 2 mediator levels in nasal tissues and secretions were measured by using a multiplex immunoassay. Eotaxin-3 and other chemokines expressed in IL-13-stimulated human sinonasal epithelial cells (HNECs) and BEAS-2B cells with or without PPIs were assessed by using ELISA, Western blotting, real-time PCR, and intracellular pH imaging. RESULTS: Nasal tissues and secretions from patients with CRSwNP had increased IL-13, eotaxin-2, and eotaxin-3 levels, and these were positively correlated with tissue eosinophil cationic protein levels and radiographic scores in patients with CRS (P < .05). IL-13 stimulation of HNECs and BEAS-2B cells dominantly induced eotaxin-3 expression, which was significantly inhibited by PPIs (P < .05). Patients with CRS taking PPIs also showed lower in vivo eotaxin-3 levels compared with those without PPIs (P < .05). Using intracellular pH imaging and altering extracellular K+, we found that IL-13 enhanced H+,K+-exchange, which was blocked by PPIs and the mechanistically unrelated H,K-ATPase inhibitor, SCH-28080. Furthermore, knockdown of ATP12A (gene for the nongastric H,K-ATPase) significantly attenuated IL-13-induced eotaxin-3 expression in HNECs. PPIs also had effects on accelerating IL-13-induced eotaxin-3 mRNA decay. CONCLUSION: Our results demonstrated that PPIs reduce IL-13-induced eotaxin-3 expression by airway epithelial cells. Furthermore, mechanistic studies suggest that the nongastric H,K-ATPase is necessary for IL-13-mediated epithelial responses, and its inhibitors, including PPIs, might be of therapeutic value in patients with CRSwNP by reducing epithelial production of eotaxin-3.
BACKGROUND:Chronic rhinosinusitis with nasal polyps (CRSwNP) is often characterized by tissue eosinophilia that is associated with poor prognosis. Recent findings that proton pump inhibitors (PPIs) directly modulate the expression of eotaxin-3, an eosinophil chemoattractant, in patients with eosinophilic diseases suggest therapeutic potential for PPIs in those with CRSwNP. OBJECTIVE: We assessed the effect of type 2 mediators, particularly IL-13 and eotaxin-3, on tissue eosinophilia and disease severity in patients with chronic rhinosinusitis (CRS). Further investigation focused on PPI suppression of eotaxin-3 expression in vivo and in vitro, with exploration of underlying mechanisms. METHODS: Type 2 mediator levels in nasal tissues and secretions were measured by using a multiplex immunoassay. Eotaxin-3 and other chemokines expressed in IL-13-stimulated human sinonasal epithelial cells (HNECs) and BEAS-2B cells with or without PPIs were assessed by using ELISA, Western blotting, real-time PCR, and intracellular pH imaging. RESULTS: Nasal tissues and secretions from patients with CRSwNP had increased IL-13, eotaxin-2, and eotaxin-3 levels, and these were positively correlated with tissue eosinophil cationic protein levels and radiographic scores in patients with CRS (P < .05). IL-13 stimulation of HNECs and BEAS-2B cells dominantly induced eotaxin-3 expression, which was significantly inhibited by PPIs (P < .05). Patients with CRS taking PPIs also showed lower in vivo eotaxin-3 levels compared with those without PPIs (P < .05). Using intracellular pH imaging and altering extracellular K+, we found that IL-13 enhanced H+,K+-exchange, which was blocked by PPIs and the mechanistically unrelated H,K-ATPase inhibitor, SCH-28080. Furthermore, knockdown of ATP12A (gene for the nongastric H,K-ATPase) significantly attenuated IL-13-induced eotaxin-3 expression in HNECs. PPIs also had effects on accelerating IL-13-induced eotaxin-3 mRNA decay. CONCLUSION: Our results demonstrated that PPIs reduce IL-13-induced eotaxin-3 expression by airway epithelial cells. Furthermore, mechanistic studies suggest that the nongastric H,K-ATPase is necessary for IL-13-mediated epithelial responses, and its inhibitors, including PPIs, might be of therapeutic value in patients with CRSwNP by reducing epithelial production of eotaxin-3.
Authors: Riikka Arppe; Tuomas Näreoja; Sami Nylund; Leena Mattsson; Sami Koho; Jessica M Rosenholm; Tero Soukka; Michael Schäferling Journal: Nanoscale Date: 2014-06-21 Impact factor: 7.790
Authors: Wytske J Fokkens; Valerie J Lund; Joachim Mullol; Claus Bachert; Isam Alobid; Fuad Baroody; Noam Cohen; Anders Cervin; Richard Douglas; Philippe Gevaert; Christos Georgalas; Herman Goossens; Richard Harvey; Peter Hellings; Claire Hopkins; Nick Jones; Guy Joos; Livije Kalogjera; Bob Kern; Marek Kowalski; David Price; Herbert Riechelmann; Rodney Schlosser; Brent Senior; Mike Thomas; Elina Toskala; Richard Voegels; De Yun Wang; Peter John Wormald Journal: Rhinol Suppl Date: 2012-03
Authors: Bruce K Tan; Quan-Zhen Li; Lydia Suh; Atsushi Kato; David B Conley; Rakesh K Chandra; Jinchun Zhou; James Norton; Roderick Carter; Monique Hinchcliff; Kathleen Harris; Anju Peters; Leslie C Grammer; Robert C Kern; Chandra Mohan; Robert P Schleimer Journal: J Allergy Clin Immunol Date: 2011-10-13 Impact factor: 10.793
Authors: Xi Zhang; Edaire Cheng; Xiaofang Huo; Chunhua Yu; Qiuyang Zhang; Thai H Pham; David H Wang; Stuart J Spechler; Rhonda F Souza Journal: PLoS One Date: 2012-11-21 Impact factor: 3.240
Authors: Jin-Young Min; Jayakar V Nayak; Kathryn E Hulse; Whitney W Stevens; Paul A Raju; Julia H Huang; Lydia A Suh; Griet A Van Roey; James E Norton; Roderick G Carter; Caroline P E Price; Ava R Weibman; Ali R Rashan; Eliver E Ghosn; Zara M Patel; Tetsuya Homma; David B Conley; Kevin C Welch; Stephanie Shintani-Smith; Anju T Peters; Leslie C Grammer; Kathleen E Harris; Atsushi Kato; Peter H Hwang; Robert C Kern; Leonore A Herzenberg; Robert P Schleimer; Bruce K Tan Journal: J Allergy Clin Immunol Date: 2017-06-16 Impact factor: 10.793
Authors: Jennifer Lavin; Jin-Young Min; Alcina K Lidder; Julia He Huang; Atsushi Kato; Kent Lam; Eric Meen; Joan S Chmiel; James Norton; Lydia Suh; Mahboobeh Mahdavinia; Kathryn E Hulse; David B Conley; Rakesh K Chandra; Stephanie Shintani-Smith; Robert C Kern; Robert P Schleimer; Bruce K Tan Journal: Laryngoscope Date: 2017-03-21 Impact factor: 3.325
Authors: Tetsuya Homma; Atsushi Kato; Masafumi Sakashita; Tetsuji Takabayashi; James E Norton; Lydia A Suh; Roderick G Carter; Kathleen E Harris; Anju T Peters; Leslie C Grammer; Jin-Young Min; Stephanie Shintani-Smith; Bruce K Tan; Kevin Welch; David B Conley; Robert C Kern; Robert P Schleimer Journal: Am J Respir Cell Mol Biol Date: 2017-09 Impact factor: 6.914
Authors: Ava R Weibman; Julia He Huang; Whitney W Stevens; Lydia A Suh; Caroline P E Price; Alcina K Lidder; David B Conley; Kevin C Welch; Stephanie Shintani-Smith; Anju T Peters; Leslie C Grammer; Atsushi Kato; Robert C Kern; Robert P Schleimer; Bruce K Tan Journal: Int Forum Allergy Rhinol Date: 2017-09-01 Impact factor: 3.858